Anna Moseley

9PUBLICATIONS
43CO-AUTHORS
Medical infection agents (incl. prions)Stochastic analysis and modellingHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AML.

Vivian M Liu, Megan Othus, Jasmine Naru

|Jan 16, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.

Anna Moseley, Michael LeBlanc, Boris Freidlin

|Nov 07, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.

Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus

|Dec 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.

Sarit Assouline, Laura C Michaelis, Megan Othus

|Nov 02, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.

Anjali S Advani, Anna Moseley, Kristen M O'Dwyer

|Feb 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.

Anjali S Advani, Anna Moseley, Kristen M O'Dwyer

Pageof 2

Frequent Collaborators

4 joint publications

Megan Othus

3 joint publications

Harry P Erba

3 joint publications

Mark R Litzow

2 joint publications

Joseph M Unger